Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy
| Registry | NCT03642990 |
|---|---|
| Status | Terminated - Enrollment challenges |
| Phase | Phase 2 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 5 (Actual) |
| Sponsor | Donna Hammond, PhD (Other); collaborators: National Cancer Institute (NCI), ChromaDex, Inc. |
| Conditions | Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV, Endometrial Cancer Stage IV |
| Interventions | Nicotinamide Riboside (Drug) |
| Dates | start 2019-11-08, primary completion 2021-08-18, completion 2022-02-24, first posted 2018-08-22, last updated 2023-04-12 |
| Locations | 2 sites in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Chemotherapy-induced Peripheral Neuropathy All trials for Breast Cancer Metastatic All trials of Nicotinamide Riboside
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for the treatment of metastatic breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, fallopian tube cancer or metastatic head and neck cancer.
Peripheral neuropathies are a dose-limiting, disabling, and debilitating side effect of virtually every known class of chemotherapeutic agent, and are referred to as chemotherapy-induced peripheral neuropathies (CIPN) (Seretny et al., 2014). The incidence and severity of CIPN increase as the cumulative dose, frequency of administration, and the number of therapeutic cycles increase. As many as 68% of patients have CIPN when assessed within 30 days of completing treatment. Patients experience paresthesias, dysesthesias (an unpleasant abnormal sensation, whether spontaneous or evoked), hyperalgesia (increased pain from a stimulus that normally provokes pain), allodynia (pain due to a stimulus that does not normally provoke pain), numbness or loss of sensation, or ongoing pain that is burning, lancinating or electric shock-like in nature. CIPN can seriously diminish a patient's quality of life, and can interfere with self-care and activities of daily living. The severity of CIPN may also necessitate reducing the dose of chemotherapeutic agent, delaying the next cycle of chemotherapy, or terminating treatment entirely (Argyriou et al., 2012; Argyriou et al., 2014; Miltenburg et al., 2014; Park et al., 2013).
Nicotinamide adenine dinucleotide (NAD+) is an essential redox coenzyme required for cell viability, basic bioenergetics, and fast axonal transport (Yang and Sauve, 2016). It plays an important role in protection against axonal injury from either mechanical or neurotoxic injury (Araki et al., 2004; Sasaki et al., 2006; Sasaki et al., 2009; Gerdts et al., 2015; Khan et al., 2014; Conforti et al., 2014; Di Stefano et al., 2015). Nicotinamide riboside (NIAGEN®) is a form of vitamin B3 and a precursor in the pathway for synthesis of NAD+ (Bieganowski et al., 2004; Trammell et al., 2016; Chi and Sauve, 2013). Oral administration of NIAGEN® increases levels of NAD+ in the blood, liver, skeletal muscle, and other tissues (Canto et al., 2012; Hamity et al, 2017; Airhart et al., 2017; Martens et al., 2018).
NIAGEN®) has been reported to prevent tactile hypersensitivity and blunt the affective dimension of nociception in a rat model of CIPN (Hamity et al., 2017) It also prevents signs of peripheral neuropathy in a mouse model of diabetes (Trammell et al., 2016) The proposed single-arm pilot phase II study will examine whether daily dosing with NIAGEN®) can prevent the progression of CIPN in persons with stage IV breast cancer or recurrent platinum-resistant ovarian, endometrial, peritoneal, or fallopian tube cancer receiving once weekly infusions of paclitaxel for 12 weeks.
In this study, persons with metastatic breast cancer, platinum-resistant recurrent ovarian, peritoneal, endometrial, or fallopian tube cancer, or platinum-resistant recurrent or metastatic head and neck cancer who are receiving weekly infusions of paclitaxel or nab-paclitaxel and anticipated to survive for at least 3 months will be offered the opportunity to enroll in this study when they develop a peripheral neuropathy of at least grade 1. Persons with peripheral neuropathy of no greater than a grade 2 from prior therapy may also enroll in this study if they are receiving weekly infusions of paclitaxel or nab-paclitaxel. Upon enrollment, health care providers will review the overall severity of the participant's neuropathy and assign a baseline grade. Participants will also complete two short questionnaires that will more specifically score how the peripheral neuropathy interferes with daily functions of living. A small sample of blood will be taken at the completion of the paclitaxel or nab-paclitaxel infusion to measure levels of paclitaxel. The participant will then be sent home with capsules of NIAGEN® to take twice daily. Each week upon return to the clinic a small sample of blood will be taken before the infusion of paclitaxel to measure biomarkers for NIAGEN®, and other samples of blood will be taken to evaluate clinical chemistries, kidney, and liver function. Another sample of blood will be obtained after the paclitaxel or nab-paclitaxel infusion to measure levels of paclitaxel or nab-paclitaxel. The health care provider will meet with the patient each week to score the overall severity of the peripheral neuropathy, and the participant will answer another questionnaire with more specific questions. Once a month, the participant will be asked to fill out a second questionnaire. Participants will take 300 mg/day NIAGEN® in the first week and 1000 mg/day in the subsequent 11 weeks. The study will conclude one week after the 12th infusion of paclitaxel or nab-paclitaxel. Health care providers will contact the participant at various times up to 6 months to monitor their status.
Beginning with completion of the trial by the 10th participant and continuing with each subsequent participant up to 39, we will use a Bayesian statistical approach (Lee and Liu, 2008; i.e. predictive probability) to determine whether NIAGEN® has prevented a worsening of the peripheral neuropathy. This approach we let us make an early determination of futility. We will also determine whether NIAGEN® has decreased the need to delay or diminish the doses of paclitaxel or nab-paclitaxel due to severity of the peripheral neuropathy. The results of this trial will inform the design of a subsequent randomized, placebo-controlled, blinded clinical trial.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NIAGEN®) | Experimental | Drug: Nicotinamide Riboside | Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks. |
Sex: All, ages: 18 Years to 85 Years
Inclusion Criteria: * Be able to give written informed consent and HIPAA authorization * Be 18 to 85 years old * Have been diagnosed with stage IV breast cancer of any type, platinum-resistant recurrent ovarian, peritoneal, endometrial, or fallopian tube cancer, or platinum-resistant recurrent or metastatic head and neck cancer and are anticipated to survive for at least three months * Have an ECOG Performance Status of 0-2 * Able to take medication orally - up to four capsules in the morning (am) and four capsules in the evening (pm). * Be undergoing infusions of paclitaxel or nab-paclitaxel for treatment of breast cancer, platinum-resistant recurrent ovarian, peritoneal, endometrial, or fallopian tube cancer, or platinum-resistant recurrent or metastatic head and neck cancer and be determined to have at least a grade 1 neuropathy based on the CTCAE version 4.03 guidelines for peripheral sensory neuropathy. Breast cancer patients may also be treated concomitantly with monoclonal antibodies to HER2 such as trastuzumab (Herceptin) and pertuzumab (Perjeta). Patients with platinum-resistant ovarian, peritoneal, endometrial, or fallopian tube cancer or platinum-resistant recurrent or metastatic head and neck cancer may also be treated concomitantly with a vascular endothelial growth receptor 2 inhibitor such as bevacizumab (Avastin) or a checkpoint inhibitor. * Females must be either postmenopausal for at least 1 year or surgically sterile for at least 6 weeks. Females of childbearing potential must have a negative pregnancy test at screening to be eligible for study participation, and agree to take appropriate precautions to avoid pregnancy from screening through follow-up. * Males must agree to take appropriate precautions to avoid fathering a child from screening through follow-up. The following methods have been determined to be more than 99% effective (<1% failure rate per year when used consistently and correctly) and are permitted under this protocol for use by the patient and his/her partner: * Complete abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the patient * Double barrier methods including condom with spermicide in conjunction with use of an intrauterine device or condom with spermicide in conjunction with use of a diaphragm * Surgical sterilization (bilateral oopherectomy with or without hysterectomy, tubal ligation or vasectomy) at least 6 weeks prior to taking study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and/or estradiol. Non-hormonal intrauterine device used as directed by provider placing this is also acceptable. Exclusion Criteria: * Pre-existent peripheral neuropathy that is unrelated to chemotherapy * Pre-existent chemotherapy-induced peripheral neuropathy greater than grade 2 * Known metastases to the brain, spinal cord or peripheral nerves, or leptomeningeal disease * Concurrent administration of a poly (ADP-Ribose) polymerase inhibitor (e.g. olaparib, rucaparib) * Concurrent administration of a platinum-based chemotherapy * Diabetes requiring management by medication * Diabetes managed by medication * Neutrophils < 1,000 cells/m3 * Hemoglobin < 8.0 g/dcl * Platelets < 100,000 cells/m3 * Creatinine clearance < 30 ml/min * AST or ALT values > 2.5 X upper limits of normal * Total bilirubin > 2.0 X upper limits of normal * Heavy alcohol use defined at > 8 drinks/week by women or 12 drinks/week by men * Chronic pain greater than 3 months duration within the past year. * Severe psychiatric illness * Pregnancy * Current imprisonment * Limitations of self-expression, defined as an inability to answer questions posed by physicians, nurses, care-givers, or other members of the investigative team or an inability to describe somatosensations. * Known HIV, not on therapy * Regular use of nutritional supplements that contain nicotinamide or NIAGEN® within the previous 30 days * Use of duloxetine (Cymbalta®) within the previous 30 days * Pancreatic insufficiency requiring exocrine enzyme replacement therapy * GI conditions where malabsorption of B complex vitamins is known to occur. * Known allergy to Cremophor vehicle used to deliver paclitaxel in its Taxol formulation * Breastfeeding
| Milestone | NIAGEN®) |
|---|---|
| Started | 5 |
| Completed | 4 |
| Not completed | 1 |
Time frame: Up to six months after end of treatment (typically 7 months total)
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| NIAGEN®) | 1/5 (20.0%) | 0/5 (0.0%) | 4/5 (80.0%) |
| Term | Organ system | NIAGEN®) |
|---|---|---|
| Nausea | Gastrointestinal disorders | 4/5 |
| mucositis oral | Gastrointestinal disorders | 1/5 |
| diarrhea | Gastrointestinal disorders | 3/5 |
| dyspepsia | Gastrointestinal disorders | 1/5 |
| vomiting | Gastrointestinal disorders | 1/5 |
| headache | Nervous system disorders | 3/5 |
| peripheral sensory neuropathy | Nervous system disorders | 2/5 |
| dizziness | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 |
| peripheral motor neuropathy | Nervous system disorders | 1/5 |
| hypocalcemia | Metabolism and nutrition disorders | 2/5 |
| hypercalcemia | Metabolism and nutrition disorders | 1/5 |
| hypokalemia | Metabolism and nutrition disorders | 1/5 |
| hypomagnesemia | Metabolism and nutrition disorders | 1/5 |
| fatigue | General disorders | 1/5 |
| localized edema | General disorders | 1/5 |
| pain | General disorders | 1/5 |
| white blood cell decreased | Investigations | 2/5 |
| alanine aminotransferase increased | Investigations | 1/5 |
| lymphocyte count decreased | Investigations | 1/5 |
| anemia | Blood and lymphatic system disorders | 1/5 |
| chest pain | Cardiac disorders | 1/5 |
| upper respiratory infection | Infections and infestations | 1/5 |
| dyspnea | Respiratory, thoracic and mediastinal disorders | 1/5 |
| nasal congestion | Respiratory, thoracic and mediastinal disorders | 1/5 |
| flushing | Vascular disorders | 1/5 |
Limitations and caveats: This trial was limited to a non-curative population of women receiving taxane chemotherapy without added platinum-based agents. Difficulty in recruiting this small population led to eventual termination of the trial. Dose escalation to 1000 mg/day did not occur for any subject due to physician concerns that subjects were not tolerating the 300 mg dose well.
| Facility | City | Country | Status |
|---|---|---|---|
| University of Iowa Hospitals and Clinics | Iowa City, Iowa | United States | |
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem, North Carolina | United States |
NIH grants: R21CA208968